Paying users zone. Data is covered by .
Get to Bristol-Myers Squibb Co. for $17.99, or
get to entire website for at least 3 months from $49.99.
Price to FCFE (P/FCFE)
Free Cash Flow to Equity (FCFE)
Bristol-Myers Squibb Co., FCFE calculation
USD $ in millions
|FCFE||Free cash flow to equity is the cash flow available to Bristol-Myers Squibb Co.’s equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made.||Bristol-Myers Squibb Co.’s FCFE increased from 2015 to 2016 and from 2016 to 2017.|
Price to FCFE Ratio, Current
Bristol-Myers Squibb Co., current P/FCFE calculation, comparison to benchmarks
|No. shares of common stock outstanding|
|Selected Financial Data (USD $)|
|Free cash flow to equity (FCFE) (in millions)|
|FCFE per share|
|Current share price (P)|
|Eli Lilly & Co.|
|Gilead Sciences Inc.|
|Johnson & Johnson|
|Merck & Co. Inc.|
|Regeneron Pharmaceuticals Inc.|
|Pharmaceuticals & Biotechnology|
Based on: 10-K (filing date: 2018-02-13).
If company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Bristol-Myers Squibb Co., historical P/FCFE calculation, comparison to benchmarks
1 Data adjusted for splits and stock dividends.
3 Close price on the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =
5 P/FCFE = Share price ÷ FCFE per share
= ÷ =
|P/FCFE||Price to free cash flow to equity is cash valuation indicator of stockholders’ equity.||Bristol-Myers Squibb Co.’s P/FCFE ratio increased from 2015 to 2016 but then slightly declined from 2016 to 2017 not reaching 2015 level.|